Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression.
Angiotensin-II (Ang-II) from extracardiac sources and intracardiac synthesis regulates cardiac homeostasis, with mitogenic and growth-promoting effects largely due to altered gene expression. Here, we assessed the possibility that angiotensin-1 (AT1R) or angiotensin-2 (AT2R) receptors on the nuclear envelope mediate effects on cardiomyocyte gene expression. Immunoblots of nucleus-enriched fractions from isolated cardiomyocytes indicated the presence of AT1R and AT2R proteins that copurified with the nuclear membrane marker nucleoporin-62 and histone-3, but not markers of plasma (calpactin-I), Golgi (GRP-78), or endoplasmic reticulum (GM130) membranes. Confocal microscopy revealed AT1R and AT2R proteins on nuclear membranes. Microinjected Ang-II preferentially bound to nuclear sites of isolated cardiomyocytes. AT1R and AT2R ligands enhanced de novo RNA synthesis in isolated cardiomyocyte nuclei incubated with [alpha-(32)P]UTP (e.g. 36.0 +/- 6.0 cpm/ng of DNA control versus 246.4 +/- 15.4 cpm/ng of DNA Ang-II, 390.1 +/- 15.5 cpm/ng of DNA L-162313 (AT1), 180.9 +/- 7.2 cpm/ng of DNA CGP42112A (AT2), p < 0.001). Ang-II application to cardiomyocyte nuclei enhanced NFkappaB mRNA expression, a response that was suppressed by co-administration of AT1R (valsartan) and/or AT2R (PD123177) blockers. Dose-response experiments with Ang-II applied to purified cardiomyocyte nuclei versus intact cardiomyocytes showed greater increases in NFkappaB mRNA levels at saturating concentrations with approximately 2-fold greater affinity upon nuclear application, suggesting preferential nuclear signaling. AT1R, but not AT2R, stimulation increased [Ca(2+)] in isolated cardiomyocyte nuclei. Inositol 1,4,5-trisphosphate receptor blockade by 2-aminoethoxydiphenyl borate prevented AT1R-mediated Ca(2+) release and attenuated AT1R-mediated transcription initiation responses. We conclude that cardiomyocyte nuclear membranes possess angiotensin receptors that couple to nuclear signaling pathways and regulate transcription. Signaling within the nuclear envelope (e.g. from intracellularly synthesized Ang-II) may play a role in Ang-II-mediated changes in cardiac gene expression, with potentially important mechanistic and therapeutic implications.
Tadevosyan
Artavazd
A
Department of Medicine, Montreal Heart Institute, H1T 1C8 Montreal, Quebec, Canada.
Maguy
Ange
A
Villeneuve
Louis R
LR
Babin
Judith
J
Bonnefoy
Arnaud
A
Allen
Bruce G
BG
Nattel
Stanley
S
D000804:Angiotensin II / Q000378:metabolism; D000818:Animals; D002467:Cell Nucleus / Q000378:metabolism*; D002469:Cell Separation; D005110:Extracellular Space / Q000378:metabolism; D005786:Gene Expression Regulation; D053496:Inositol 1,4,5-Trisphosphate Receptors / Q000378:metabolism; D042541:Intracellular Space / Q000378:metabolism; D008297:Male; D008845:Microinjections; D009206:Myocardium / Q000166:cytology / Q000378:metabolism; D032383:Myocytes, Cardiac / Q000378:metabolism*; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D021381:Protein Transport; D051381:Rats; D017208:Rats, Wistar; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics / Q000378:metabolism*; D044139:Receptor, Angiotensin, Type 2 / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D013347:Subcellular Fractions / Q000378:metabolism; D014158:Transcription, Genetic
D053496:Inositol 1,4,5-Trisphosphate Receptors; D016328:NF-kappa B; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D000804:Angiotensin II
Diabetes. 2008 Dec;57(12):3297-306
18829990
Cardiovasc Res. 2006 Jul 1;71(1):69-78
16631628
J Physiol. 2007 Oct 15;584(Pt 2):601-11
17761776
Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12457-62
18711143
Tissue Cell. 1994 Dec;26(6):943-55
7886680
Endocrinology. 1992 Jun;130(6):3641-9
1597161
Endocr Rev. 2000 Feb;21(1):90-113
10696571
Cell. 1993 Dec 3;75(5):977-84
8252633
Methods. 2001 Dec;25(4):402-8
11846609
Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H939-48
17483239
Circ Res. 1996 Oct;79(4):765-72
8831500
Immunol Cell Biol. 2000 Aug;78(4):387-94
10947863
Science. 1971 Jun 11;172(3988):1138-9
4324923
Hypertension. 2006 May;47(5):894-900
16585419
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15792-7
9861049
Hypertension. 2007 Jun;49(6):1196-201
17452509
J Biol Chem. 2003 Aug 1;278(31):29153-63
12756260
J Clin Pharmacol. 2008 Mar;48(3):344-50
18223145
J Cell Sci. 2004 Jul 1;117(Pt 15):3087-94
15226390
Endocrinology. 1992 Jul;131(1):374-80
1612017
Circ Res. 2008 Oct 24;103(9):992-1000
18802028
Br J Pharmacol. 2001 Apr;132(7):1590-6
11264254
Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1900-7
17586619
J Hypertens. 2007 Aug;25(8):1643-9
17620961
Circ Res. 2002 May 31;90(10):1135-41
12039805
Nat Clin Pract Cardiovasc Med. 2007 Oct;4(10):549-57
17893683
N Engl J Med. 1997 Apr 10;336(15):1066-71
9091804
Hypertension. 1998 Dec;32(6):976-82
9856960
Biol Res. 2006;39(3):541-53
17106585
Cell. 1998 Jan 9;92(1):17-23
9489696
Brain Res Mol Brain Res. 1996 Jun;38(2):179-90
8793106
Regul Pept. 2006 Jan 15;133(1-3):10-2
16325280
Proc Soc Exp Biol Med. 1991 Mar;196(3):280-3
1998005
Nature. 2000 Sep 7;407(6800):94-8
10993080
Lancet. 2002 Mar 23;359(9311):995-1003
11937178
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17818-23
19008357
J Biol Chem. 2008 Oct 10;283(41):27859-27870
18632662
J Hypertens. 2003 Nov;21(11):2175-82
14597862
EMBO J. 1999 Apr 1;18(7):1723-9
10202136
Br J Cancer. 2004 Mar 8;90(5):1059-68
14997208
J Mol Med (Berl). 2002 Jun;80(6):359-66
12072911
Regul Pept. 2004 Aug 15;120(1-3):5-13
15177915
Am J Physiol Cell Physiol. 2008 Apr;294(4):C1034-45
18256274
J Am Coll Cardiol. 2005 Mar 1;45(5):705-11
15734614